| Cas No.: | 2376146-48-2 |
| Chemical Name: | ZN-c3 |
| Synonyms: | ZN-C3;ZN-C3 [WHO-DD];9J13XU96Z1;3H-Pyrazolo(3,4-d)pyrimidin-3-one, 1-((7R)-7-ethyl-6,7-dihydro-7-hydroxy-5H-cyclopenta(b)pyridin-2-yl)-1,2-dihydro-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-;ZN-c3 |
| SMILES: | O[C@@]1(CC)C2C(=CC=C(N3C4C(=CN=C(NC5C=CC(=CC=5)N5CCN(C)CC5)N=4)C(N3CC=C)=O)N=2)CC1 |
| Formula: | C29H34N8O2 |
| M.Wt: | 526.632665157318 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | ZN-c3 is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer. |
| Target: | IC50: 3.9 nM (Wee1)[1] |
| In Vivo: | ZN-c3 (80 mg/kg; p.o.; 28 days) can effectively shrank tumors at 80 mg/kg as a single agent[1]. ZN-c3 shows excellent exposures and bioavailability in the dog PK study[1]. |
| In Vitro: | ZN-c3 IC50 is 103 nM in H23c cells[1]. |
| References: | [1]. Huang PQ, et al. Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer [published online ahead of print, 2021 Aug 23]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01121. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
.png)